Kiniksa Pharmaceuticals International (KNSA) Receivables - Net (2021 - 2025)
Kiniksa Pharmaceuticals International (KNSA) has disclosed Receivables - Net for 5 consecutive years, with $15.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net fell 62.63% year-over-year to $15.6 million, compared with a TTM value of $15.6 million through Dec 2025, down 62.63%, and an annual FY2025 reading of $15.6 million, down 62.63% over the prior year.
- Receivables - Net was $15.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $51.7 million in the prior quarter.
- Across five years, Receivables - Net topped out at $51.7 million in Q3 2025 and bottomed at $2.6 million in Q2 2021.
- Average Receivables - Net over 5 years is $19.5 million, with a median of $16.0 million recorded in 2024.
- The sharpest move saw Receivables - Net crashed 74.78% in 2023, then surged 718.41% in 2024.
- Year by year, Receivables - Net stood at $4.0 million in 2021, then soared by 217.69% to $12.7 million in 2022, then skyrocketed by 67.98% to $21.3 million in 2023, then surged by 96.2% to $41.7 million in 2024, then tumbled by 62.63% to $15.6 million in 2025.
- Business Quant data shows Receivables - Net for KNSA at $15.6 million in Q4 2025, $51.7 million in Q3 2025, and $31.9 million in Q2 2025.